Silexion Therapeutics (SLXN) announced the recent successful submission of a clinical trial application, or CTA, to Germany for its planned Phase 2/3 clinical trial of its lead, small interfering RNA product candidate, SIL204, in patients with locally advanced pancreatic cancer. The CTA was submitted through the EU Clinical Trials Information System, with Germany serving as the Reporting Member State – the country that will lead the scientific assessment of the trial across the European Union.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLXN:
- Silexion advances SIL204 to EU Phase 2/3 pancreatic trial
- Silexion Therapeutics Announces Immediate Board Membership Change
- Silexion Therapeutics approved to initiate Phase 2/3 clinical trial of SIL204
- Silexion gains approval for SIL204 pancreatic cancer trial
- Silexion Shareholders Reject Capital Increase and Plan Amendments